ARTL Artelo Biosciences
Price Chart
Executive Summary
Artelo Biosciences announced a private placement of 3,188,407 shares (or pre-funded warrants) and accompanying warrants to raise approximately $11.0 million in gross proceeds, with potential additional proceeds of $20.4 million if all warrants are exercised. The funds will be used for working capital, general corporate purposes, and repayment of bridge debt.
Key Financial Metrics
Actionable Insight
Monitor filing of the resale registration statement, which could increase share float and near-term trading pressure. Watch for warrant exercise activity, which would bring in additional capital but further dilute shareholders.
Key Facts
- Private placement of 3,188,407 shares or pre-funded warrants and warrants for up to 6,376,814 shares
- Combined purchase price of $3.45 per share and accompanying warrant
- Warrants exercisable immediately at $3.20 per share, expiring 5.5 years from effectiveness date
- Gross proceeds expected to be $11.0 million, with potential additional $20.4 million if warrants are fully exercised
- Proceeds to be used for working capital, general corporate purposes, and repayment of certain bridge debt
- H.C. Wainwright & Co. acting as exclusive placement agent
- Offering exempt under Section 4(a)(2) and Regulation D; resale registration to be filed
Financial Impact
$11.0 million in immediate gross proceeds, with up to $20.4 million in potential future proceeds if warrants are exercised
Risk Factors
- Significant dilution from both the issuance of new shares and potential exercise of warrants
- No assurance that warrants will be exercised, leaving future funding needs uncertain
- Use of proceeds includes repayment of bridge debt, which may indicate prior liquidity pressure
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263855 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
18d ago
|
8-K
| $1.46 $1.46 | · 0.00% | ▼ −0.05% | $1.36 (+6.85%) |
|
May 18, 2026
27d ago
|
424B5
| $1.36 $1.40 | ▲ +2.57% | ▲ +0.33% | $1.36 (+0.00%) |
|
May 15, 2026
4w ago
|
8-K
| $1.46 $1.71 | ▲ +17.12% | ▲ +15.50% | $1.36 (−6.85%) |
|
May 14, 2026
4w ago
|
S-3/A
| $1.84 $1.19 | ▲ +35.33% | ▲ +36.29% | $1.36 (+26.09%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $3.57 $3.30 | ▼ −7.56% | ▼ −9.25% | $1.36 (−61.90%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.53 $3.77 | ▼ −16.69% | ▼ −17.60% | $1.36 (−69.94%) |
|
Apr 7, 2026
9w ago
|
S-1
| $6.84 $5.31 | ▲ +22.37% | ▲ +25.89% | $1.36 (+80.12%) |
|
Apr 7, 2026
9w ago
|
8-K
| $7.29 $5.41 | ▼ −25.79% | ▼ −31.12% | $1.36 (−81.34%) |
|
Mar 31, 2026
10w ago
|
EFFECT
| $7.58 $6.84 | ▲ +9.76% | ▲ +13.71% | $1.36 (+82.06%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $7.58 $6.84 | ▲ +9.76% | ▲ +13.71% | $1.36 (+82.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access